Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is rhabdomyosarcoma?
Rhabdomyosarcoma is a type of soft-tissue sarcoma that arises from cells which would normally develop into skeletal muscle — the muscles we move on purpose. Although it can develop almost anywhere in the body, it most commonly appears in the head and neck (including around the eye and in the sinuses), the urinary and reproductive organs (such as the bladder, prostate, or vagina), and the arms and legs. Rhabdomyosarcoma is primarily a cancer of children and teenagers, though it can occur in adults. Because it can grow in so many locations, the symptoms depend on where it starts — a visible or felt lump, a bulging eye, nasal congestion or bleeding, blood in the urine or trouble urinating, or pain. Rhabdomyosarcoma is treated as a whole-body disease from the start, meaning chemotherapy is always part of the plan to treat both the visible tumor and any microscopic spread, while radiation and sometimes surgery are used to control the original tumor. With this combined, coordinated approach delivered by a specialized pediatric or sarcoma team, the majority of children with rhabdomyosarcoma are cured. Treatment is carefully tailored to balance cure with protecting growth and long-term function, especially in young patients.
The main types
Doctors group rhabdomyosarcoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Embryonal rhabdomyosarcoma | The most common type, usually in younger children; it often occurs in the head and neck or genital and urinary areas and generally has a more favorable outlook. |
| Botryoid (a subtype of embryonal) | A grape-like form of embryonal rhabdomyosarcoma that arises in hollow organs such as the bladder or vagina; it tends to be found early and responds well. |
| Alveolar rhabdomyosarcoma | A type more common in older children and teens, often in the arms, legs, or trunk; it tends to be more aggressive and usually calls for more intensive treatment. |
| Pleomorphic rhabdomyosarcoma | A rare form seen mainly in adults; it behaves like other adult high-grade soft-tissue sarcomas. |
Staging, in plain terms
Rhabdomyosarcoma is not staged with the ordinary adult TNM system alone. Instead, specialists combine several pieces of information to place each child into a low-, intermediate-, or high-risk group, which then guides how intensive treatment should be. The pieces include: where the tumor started (some sites, such as around the eye, are more favorable), how large it is and whether it can be removed by surgery, whether it has spread to lymph nodes or to distant parts of the body, and its subtype and genetic features (embryonal versus alveolar, and the presence of a specific fusion gene). This risk-group approach lets the team match the strength of chemotherapy and radiation to each child's situation — using enough treatment to cure while sparing lower-risk children from unnecessarily harsh therapy. Most children fall into the low- or intermediate-risk groups and have good cure rates.
| Risk-group system (stage + clinical group + biology), not standard TNM alone | What it generally means |
|---|---|
| Low risk | A tumor in a favorable location that is small or fully removable, without spread; treated with less intensive chemotherapy and radiation, with high cure rates. |
| Intermediate risk | A tumor in a less favorable site, larger, or not fully removable, without distant spread; treated with combined chemotherapy and radiation and good chances of cure. |
| High risk | Cancer that has spread to distant sites or has unfavorable biology; treated with more intensive combined therapy and the focus of many clinical trials. |
The standard of care
Rhabdomyosarcoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Chemotherapy
Chemotherapy is always part of treatment and is given to every patient; it treats both the main tumor and any microscopic cancer cells that may have spread, and it shrinks tumors to make local treatment more effective.
Radiation therapy
Radiation is a key way to control the original tumor, especially when surgery cannot fully remove it or would harm important structures; it is central to treating tumors near the eye, in the head and neck, and in the pelvis.
Surgery
When a tumor can be removed safely without causing major harm, surgery is used; in many locations, however, radiation is preferred to preserve function such as vision or bladder control.
Coordinated multidisciplinary care
A team of pediatric oncologists, radiation oncologists, surgeons, and supportive specialists coordinates the timing of chemotherapy, radiation, and any surgery for the best cure rate with the least long-term harm.
How radiation treatment works
Radiation uses focused high-energy beams to damage the DNA inside cancer cells so they can no longer grow and divide. In rhabdomyosarcoma, radiation is a key way to control the original tumor — the place it started — particularly when surgery cannot remove it completely or would damage important structures such as the eye, bladder, or facial growth. Because rhabdomyosarcoma is treated as a whole-body disease, radiation is combined with chemotherapy, which treats microscopic spread and helps shrink the tumor first. Treatment is given as a series of short daily sessions over several weeks, carefully timed around chemotherapy. In children, sparing healthy growing tissue is a top priority, so advanced techniques are used: IMRT shapes the dose around the tumor, proton therapy reduces dose to developing bones and organs, and brachytherapy can deliver a focused dose for certain pelvic tumors while preserving function. The radiation oncologist chooses the technique and dose based on the tumor's size, location, and how well it responded to chemotherapy. Side effects depend on the area treated and are watched closely and managed by the team, with special attention to protecting growth, vision, fertility, and organ function in young patients. The overall plan is designed to cure the cancer while protecting a child's long-term development and quality of life.
The main ways radiation is delivered for rhabdomyosarcoma:
Intensity-modulated radiation therapy (IMRT)
IMRT shapes the radiation dose tightly around the tumor while sparing nearby developing tissues, which is especially important in children to protect growth, vision, and organ function.
Proton therapy
Proton beams stop after reaching the tumor, delivering little dose beyond it; in children this can reduce radiation to growing bones, the brain, and other organs, potentially lowering long-term side effects and the risk of second cancers.
Brachytherapy
For selected tumors in sites such as the bladder, prostate, or vagina, placing radioactive sources directly at the tumor delivers a focused dose while sparing surrounding organs and preserving function.
Radiation timed with chemotherapy
Radiation is carefully scheduled around chemotherapy cycles so the two treatments work together to control the tumor while keeping side effects manageable.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Risk-adapted combined therapy: Decades of cooperative-group trials established that matching the intensity of chemotherapy and radiation to each child's risk group cures the majority of patients while sparing lower-risk children from excessive treatment.[1]
Pediatric cooperative-group rhabdomyosarcoma trials
Proton therapy to protect growing tissue: Studies show proton therapy can reduce radiation to developing bones, the brain, and other organs in children, lowering certain long-term side effects and the risk of second cancers while maintaining tumor control.[2]
Pediatric proton therapy research
Fusion-gene biology refines risk: Research found that the presence or absence of a specific fusion gene predicts behavior better than subtype alone, and this molecular information is now used to assign risk and tailor treatment.[3]
Rhabdomyosarcoma molecular studies
Common questions
Will my child need chemotherapy even if the tumor is removed? Yes. Rhabdomyosarcoma is treated as a whole-body disease, so chemotherapy is given to every patient — even after surgery — to treat any microscopic cancer cells that may have spread. Radiation is often added to control the area where the tumor started.
Is radiation safe for a child? Radiation is used carefully in children, with advanced techniques such as IMRT, proton therapy, and sometimes brachytherapy chosen specifically to spare growing tissue and protect vision, organ function, and development. The team weighs the benefits of curing the cancer against long-term effects and selects the gentlest effective approach.
What are the chances of cure? Most children with rhabdomyosarcoma are cured, especially those in the low- and intermediate-risk groups. The outlook depends on where the tumor started, its size and subtype, whether it has spread, and how it responds to chemotherapy. Your child's team can give a prognosis tailored to their specific situation.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.